115195
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
2025 年基孔肯雅病毒：流行病学、免疫发病机制和疫苗开发——一项叙述性综述
Authors Zhao C, Ge Z, Zhang T, Jiang Z, Tian D, Chen Z
Received 12 September 2025
Accepted for publication 6 January 2026
Published 13 January 2026 Volume 2026:19 567134
DOI https://doi.org/10.2147/IDR.S567134
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Héctor Mora-Montes
Chenxi Zhao,* Ziruo Ge,* Tingyu Zhang, Zhouling Jiang, Di Tian, Zhihai Chen
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhihai Chen, National Key Laboratory of Intelligent Tracking and Forecasting for infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China, Email chenzhihai0001@126.com Di Tian, National Key Laboratory of Intelligent Tracking and Forecasting for infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China, Email tiandi412@hotmail.com
Abstract: Chikungunya is an arboviral disease caused by infection with chikungunya virus (CHIKV), an alphavirus transmitted primarily by Aedes aegypti and Aedes albopictus. Over the past two decades, chikungunya has re-emerged across Africa, Asia, the Indian Ocean, Europe, and the Americas, with 119 countries and territories reporting local transmission up to 2024. This expansion reflects a widening geographic range with greater risk of introduction and spreads through mosquito vectors, leaving larger populations susceptible to infection. Following inoculation by an infected mosquito, viral replication leads to viremia and the abrupt onset of fever, severe joint pain with swelling, myalgia, and rash. These clinical manifestations are driven by the host immune response to infection, which also influence disease severity and clinical outcomes. Although most patients recover within weeks, a proportion develop persistent arthralgia or chronic arthritis lasting months to years, contributing to the overall disease burden. Although both the live-attenuated vaccine IXCHIQ and the virus-like particle vaccine VIMKUNYA have been approved, the license for IXCHIQ was recently suspended due to safety concerns. Recent outbreaks of chikungunya fever have driven sustained research, leading to deeper insights into disease pathogenesis, host immune responses and chronic inflammation. In this narrative review, we summarize recent advances up to 2025 in the epidemiology, host receptors, pathogenesis, clinical manifestations, immune responses, mother-to-child transmission, and vaccines development of CHIKV.
Keywords: chikungunya, arthritis, cytokine, mother-to-child transmission, vaccine
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhihai Chen, National Key Laboratory of Intelligent Tracking and Forecasting for infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China, Email chenzhihai0001@126.com Di Tian, National Key Laboratory of Intelligent Tracking and Forecasting for infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China, Email tiandi412@hotmail.com
Abstract: Chikungunya is an arboviral disease caused by infection with chikungunya virus (CHIKV), an alphavirus transmitted primarily by Aedes aegypti and Aedes albopictus. Over the past two decades, chikungunya has re-emerged across Africa, Asia, the Indian Ocean, Europe, and the Americas, with 119 countries and territories reporting local transmission up to 2024. This expansion reflects a widening geographic range with greater risk of introduction and spreads through mosquito vectors, leaving larger populations susceptible to infection. Following inoculation by an infected mosquito, viral replication leads to viremia and the abrupt onset of fever, severe joint pain with swelling, myalgia, and rash. These clinical manifestations are driven by the host immune response to infection, which also influence disease severity and clinical outcomes. Although most patients recover within weeks, a proportion develop persistent arthralgia or chronic arthritis lasting months to years, contributing to the overall disease burden. Although both the live-attenuated vaccine IXCHIQ and the virus-like particle vaccine VIMKUNYA have been approved, the license for IXCHIQ was recently suspended due to safety concerns. Recent outbreaks of chikungunya fever have driven sustained research, leading to deeper insights into disease pathogenesis, host immune responses and chronic inflammation. In this narrative review, we summarize recent advances up to 2025 in the epidemiology, host receptors, pathogenesis, clinical manifestations, immune responses, mother-to-child transmission, and vaccines development of CHIKV.
Keywords: chikungunya, arthritis, cytokine, mother-to-child transmission, vaccine